Heron Therapeutics (NASDAQ:HRTX) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.
A number of other brokerages also recently issued reports on HRTX. Cantor Fitzgerald set a $31.00 price target on shares of Heron Therapeutics and gave the stock a “buy” rating in a research note on Thursday, October 26th. ValuEngine upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 30th. Northland Securities initiated coverage on shares of Heron Therapeutics in a research note on Wednesday, September 27th. They issued an “outperform” rating and a $40.00 price target for the company. Mizuho reiterated a “buy” rating and issued a $28.00 price target on shares of Heron Therapeutics in a research note on Friday, December 8th. Finally, Noble Financial reiterated a “buy” rating and issued a $24.00 price target on shares of Heron Therapeutics in a research note on Friday, October 6th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $28.82.
Heron Therapeutics (NASDAQ HRTX) opened at $23.20 on Friday. Heron Therapeutics has a 12 month low of $12.25 and a 12 month high of $23.35. The company has a quick ratio of 2.02, a current ratio of 2.12 and a debt-to-equity ratio of 0.62. The company has a market cap of $1,479.34, a P/E ratio of -6.12 and a beta of 2.13.
In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of the firm’s stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total transaction of $151,680.00. Following the sale, the vice president now owns 7,584 shares of the company’s stock, valued at $151,680. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 19.93% of the stock is currently owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in HRTX. Janus Henderson Group PLC acquired a new stake in Heron Therapeutics during the second quarter worth approximately $78,134,000. Perceptive Advisors LLC acquired a new stake in Heron Therapeutics during the third quarter worth approximately $5,329,000. Vanguard Group Inc. raised its holdings in Heron Therapeutics by 11.8% during the second quarter. Vanguard Group Inc. now owns 2,096,465 shares of the biotechnology company’s stock worth $29,036,000 after purchasing an additional 221,362 shares in the last quarter. Rubric Capital Management LP raised its holdings in Heron Therapeutics by 11.8% during the third quarter. Rubric Capital Management LP now owns 1,900,000 shares of the biotechnology company’s stock worth $30,685,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Chartwell Investment Partners LLC acquired a new stake in Heron Therapeutics during the third quarter worth approximately $2,340,000. 98.21% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/20/bidaskclub-upgrades-heron-therapeutics-hrtx-to-buy.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.